Koelis Announces New Compact 3D Probe to Improve Workflow and Reprocessing
25 sept. 2024 09h07 HE
|
Koelis
Koelis is pleased to announce the introduction of our new 3D ultrasound probe that maximizes auto reprocessing compatibility.
Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement
23 sept. 2024 15h34 HE
|
Comprehensive Urology
Comprehensive Urology of Los Angeles studies STUD Protocol for male enhancement in survivors of prostate cancer during Prostate Cancer Awareness Month.
La « Distinguished Gentleman's Drive » fête sa quatrième année dimanche le 29 septembre 2024
23 sept. 2024 07h30 HE
|
Movember Canada
TORONTO, 23 sept. 2024 (GLOBE NEWSWIRE) -- Le Distinguished Gentleman's Drive (DGD) est une célébration du style classique. C'est un événement de levée de fonds sur la route qui réunit des...
The Distinguished Gentleman’s Drive Celebrates Its Fourth Year on Sunday, September 29, 2024
23 sept. 2024 07h30 HE
|
Movember Canada
TORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Distinguished Gentleman’s Drive (DGD) is a celebration of classic style. It’s an on-road fundraising event that unites classic cars – aged 40 years...
Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion Biopsy
20 sept. 2024 09h07 HE
|
Koelis
Koelis finalizes partnership with Deep Health for AI-powered prostate MRI interpretation and guidance in fusion biopsy for prostate cancer.
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
15 sept. 2024 08h45 HE
|
Lantheus Holdings, Inc.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3%...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
15 sept. 2024 03h00 HE
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
12 sept. 2024 06h58 HE
|
MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
The National Civil Rights Museum Hosts Catalyst for Change Panel on Prostate Cancer Health Inequities in Black Men
10 sept. 2024 16h22 HE
|
National Civil Rights Museum
Memphis, TN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum (NCRM) is proud to present "Tackling Prostate Cancer Disparities in Black Men" as part of its Catalyst for Change...
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
10 sept. 2024 04h30 HE
|
Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...